Abstract
Clinical pathogen sequencing has significant potential to drive informed treatment of patients with unknown bacterial infection. However, the lack of rapid sequencing technologies with concomitant analysis has impeded clinical adoption in infection diagnosis. Here we demonstrate that commercially-available Nanopore sequencing devices can identify bacterial species and strain information with less than one hour of sequencing time, initial drug-resistance profiles within 2 hours, and a complete resistance profile within 12 hours. We anticipate these devices and associated analysis methods may become useful clinical tools to guide appropriate therapy in time-critical clinical presentations such as bacteraemia and sepsis.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.